MX361618B - Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas. - Google Patents
Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas.Info
- Publication number
- MX361618B MX361618B MX2011010311A MX2011010311A MX361618B MX 361618 B MX361618 B MX 361618B MX 2011010311 A MX2011010311 A MX 2011010311A MX 2011010311 A MX2011010311 A MX 2011010311A MX 361618 B MX361618 B MX 361618B
- Authority
- MX
- Mexico
- Prior art keywords
- making
- methods
- same
- pharmaceutical formulations
- derivatives
- Prior art date
Links
- YHKWFDPEASWKFQ-UHFFFAOYSA-N 3-nitrobenzene-1,2-diol Chemical class OC1=CC=CC([N+]([O-])=O)=C1O YHKWFDPEASWKFQ-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16579409P | 2009-04-01 | 2009-04-01 | |
| PCT/PT2010/000015 WO2010114405A2 (en) | 2009-04-01 | 2010-03-31 | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2011010311A MX2011010311A (es) | 2012-03-07 |
| MX361618B true MX361618B (es) | 2018-12-13 |
Family
ID=42229943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011010311A MX361618B (es) | 2009-04-01 | 2010-03-31 | Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20100256194A1 (enExample) |
| EP (1) | EP2413913B1 (enExample) |
| JP (2) | JP5864410B2 (enExample) |
| KR (1) | KR101824257B1 (enExample) |
| CN (2) | CN102438595B (enExample) |
| AU (1) | AU2010231962B2 (enExample) |
| BR (1) | BRPI1016132B8 (enExample) |
| CA (1) | CA2757418C (enExample) |
| DK (1) | DK2413913T3 (enExample) |
| ES (1) | ES2915698T3 (enExample) |
| MX (1) | MX361618B (enExample) |
| PL (1) | PL2413913T3 (enExample) |
| PT (1) | PT2413913T (enExample) |
| RU (1) | RU2550133C2 (enExample) |
| WO (1) | WO2010114405A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006272978B2 (en) | 2005-07-26 | 2012-06-07 | Bial - Portela & Ca, S.A. | Nitrocatechol derivatives as COMT inhibitors |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| CN101631548B (zh) | 2007-01-31 | 2014-08-27 | 比艾尔-坡特拉有限公司 | Comt抑制剂的单次药物剂量单元和药物组合物 |
| AU2009226221A1 (en) | 2008-03-17 | 2009-09-24 | Bial - Portela & Ca., S.A. | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol |
| KR102023255B1 (ko) * | 2009-04-01 | 2019-09-19 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법 |
| US20140045900A1 (en) * | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| BR112014014341A2 (pt) | 2011-12-13 | 2017-08-22 | Bial Portela & Ca Sa | Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica |
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| WO2016083863A1 (en) | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
| KR20200100075A (ko) * | 2017-12-18 | 2020-08-25 | 유니켐 레버러토리스 리미티드 | 오피카폰 및 그의 중간체의 제조방법 |
| FI3758708T3 (fi) * | 2018-03-01 | 2025-02-18 | Astrazeneca Ab | (2s)-{(1s)-1-syano-2-[4-(3-metyyli-2-okso-2,3-dihydro-1,3-bentsoksatsol-5-yyli)fenyyli]etyyli}-1,4-oksatsepaani-2-karboksamidia käsittäviä farmaseuttisia koostumuksia |
| KR20210032431A (ko) | 2018-07-17 | 2021-03-24 | 인스메드 인코포레이티드 | 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드 |
| EP3860602A1 (en) | 2018-10-05 | 2021-08-11 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| WO2020072886A1 (en) | 2018-10-05 | 2020-04-09 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| CN120478288A (zh) | 2020-03-13 | 2025-08-15 | 巴尔-波特拉及康邦亚股份有限公司 | 微粉化的奥匹卡朋 |
| GB202011709D0 (en) | 2020-07-28 | 2020-09-09 | Bial Portela & Ca Sa | Solid dispersion of opicapone |
| GB202016425D0 (en) | 2020-10-16 | 2020-12-02 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| WO2022131944A1 (en) | 2020-12-17 | 2022-06-23 | Bial-Portela & Ca., S.A. | Treatment regimens for early idiopathic parkinson's disease |
| US20240300930A1 (en) * | 2021-02-26 | 2024-09-12 | Msn Laboratories Private Limited, R&D Center | Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide |
| GB202212082D0 (en) | 2022-08-18 | 2022-10-05 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| WO2024242579A1 (en) | 2023-05-25 | 2024-11-28 | Bial-Portela & Ca., S.A. | Treatment regimens for early idiopathic parkinson's disease |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1532178A (en) * | 1921-07-25 | 1925-04-07 | Louis A Godbold | Lubricator |
| US3647809A (en) * | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
| US4085563A (en) * | 1977-01-31 | 1978-04-25 | Campbell Soup Company | Cookie dispensing apparatus |
| US4264573A (en) * | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
| US4368668A (en) * | 1981-05-15 | 1983-01-18 | Veb Kombinat Polygraph "Werner Lamberz" Leipzig | Printing plate mounting arrangement |
| US5236952A (en) * | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| YU213587A (en) * | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| US6361794B1 (en) * | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
| US6206110B1 (en) * | 1996-09-09 | 2001-03-27 | Smith International, Inc. | Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit |
| JP2002526482A (ja) * | 1998-09-18 | 2002-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｐ３８のインヒビター |
| GB2344819A (en) * | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| DK1356046T3 (da) * | 2000-11-28 | 2010-03-01 | Zymogenetics L L C | Cytokinreceptor zcytoR19 |
| US20040097555A1 (en) * | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
| DE60234812D1 (de) * | 2001-01-29 | 2010-02-04 | Shionogi & Co | Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält |
| CA2449544A1 (en) * | 2001-06-08 | 2002-12-19 | Cytovia, Inc. | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs |
| AU2003303373B8 (en) * | 2002-12-18 | 2010-06-10 | Cytovia, Inc. | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| WO2005006945A2 (en) * | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| EP2409690B1 (en) * | 2003-09-29 | 2022-11-09 | Novo Nordisk Health Care AG | Improved stability of progestogen formulations |
| US7300406B2 (en) * | 2003-09-30 | 2007-11-27 | Carter Vandette B | Medical examination apparatus |
| GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| JP2007535551A (ja) * | 2004-04-28 | 2007-12-06 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｒｏｃｋおよび他のプロテインキナーゼの阻害剤として有用な組成物 |
| EP1625849A1 (en) * | 2004-08-09 | 2006-02-15 | Liconsa, Liberacion Controlada de Sustancias Activas, S.A. | Pharmaceutical composition comprising drospirenone and ethynylestradiol |
| GB0510143D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| US20080051441A1 (en) * | 2004-12-28 | 2008-02-28 | Astrazeneca Ab | Aryl Sulphonamide Modulators |
| US20060257473A1 (en) * | 2005-05-11 | 2006-11-16 | Porranee Puranajoti | Extended release tablet |
| WO2006132914A2 (en) * | 2005-06-03 | 2006-12-14 | Abbott Laboratories | Cyclobutyl amine derivatives |
| JP2007024970A (ja) * | 2005-07-12 | 2007-02-01 | Miyakawa:Kk | 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置 |
| AU2006272978B2 (en) * | 2005-07-26 | 2012-06-07 | Bial - Portela & Ca, S.A. | Nitrocatechol derivatives as COMT inhibitors |
| US20070048384A1 (en) * | 2005-08-26 | 2007-03-01 | Joerg Rosenberg | Pharmaceutical compositions |
| EP1845097A1 (en) * | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| JP2008162955A (ja) * | 2006-12-28 | 2008-07-17 | Chugai Pharmaceut Co Ltd | バリン含有高密度顆粒剤 |
| CN101631548B (zh) * | 2007-01-31 | 2014-08-27 | 比艾尔-坡特拉有限公司 | Comt抑制剂的单次药物剂量单元和药物组合物 |
| AR065802A1 (es) * | 2007-03-22 | 2009-07-01 | Schering Corp | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas |
| AU2009226221A1 (en) * | 2008-03-17 | 2009-09-24 | Bial - Portela & Ca., S.A. | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol |
-
2010
- 2010-03-31 JP JP2012503351A patent/JP5864410B2/ja active Active
- 2010-03-31 PT PT107143869T patent/PT2413913T/pt unknown
- 2010-03-31 CN CN201080022455.3A patent/CN102438595B/zh active Active
- 2010-03-31 AU AU2010231962A patent/AU2010231962B2/en active Active
- 2010-03-31 EP EP10714386.9A patent/EP2413913B1/en active Active
- 2010-03-31 RU RU2011143619/15A patent/RU2550133C2/ru active IP Right Revival
- 2010-03-31 CN CN201610184873.1A patent/CN105816456A/zh active Pending
- 2010-03-31 PL PL10714386.9T patent/PL2413913T3/pl unknown
- 2010-03-31 BR BRPI1016132A patent/BRPI1016132B8/pt active IP Right Grant
- 2010-03-31 ES ES10714386T patent/ES2915698T3/es active Active
- 2010-03-31 US US12/750,957 patent/US20100256194A1/en not_active Abandoned
- 2010-03-31 KR KR1020117025867A patent/KR101824257B1/ko active Active
- 2010-03-31 DK DK10714386.9T patent/DK2413913T3/da active
- 2010-03-31 MX MX2011010311A patent/MX361618B/es active IP Right Grant
- 2010-03-31 WO PCT/PT2010/000015 patent/WO2010114405A2/en not_active Ceased
- 2010-03-31 CA CA2757418A patent/CA2757418C/en active Active
-
2015
- 2015-08-27 JP JP2015168153A patent/JP6336420B2/ja active Active
-
2018
- 2018-09-05 US US16/122,643 patent/US20190008774A1/en not_active Abandoned
-
2020
- 2020-12-15 US US17/122,013 patent/US20210315824A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN105816456A (zh) | 2016-08-03 |
| BRPI1016132A2 (pt) | 2016-04-19 |
| US20210315824A1 (en) | 2021-10-14 |
| JP6336420B2 (ja) | 2018-06-06 |
| KR101824257B1 (ko) | 2018-01-31 |
| RU2550133C2 (ru) | 2015-05-10 |
| JP5864410B2 (ja) | 2016-02-17 |
| WO2010114405A3 (en) | 2011-01-06 |
| KR20120008040A (ko) | 2012-01-25 |
| US20190008774A1 (en) | 2019-01-10 |
| ES2915698T3 (es) | 2022-06-24 |
| JP2012522764A (ja) | 2012-09-27 |
| CN102438595A (zh) | 2012-05-02 |
| BRPI1016132B1 (pt) | 2020-11-24 |
| US20100256194A1 (en) | 2010-10-07 |
| WO2010114405A2 (en) | 2010-10-07 |
| CA2757418C (en) | 2021-06-15 |
| AU2010231962A1 (en) | 2011-11-17 |
| EP2413913A2 (en) | 2012-02-08 |
| EP2413913B1 (en) | 2022-05-18 |
| PL2413913T3 (pl) | 2022-09-26 |
| CN102438595B (zh) | 2016-04-27 |
| BRPI1016132B8 (pt) | 2021-05-25 |
| MX2011010311A (es) | 2012-03-07 |
| JP2016020369A (ja) | 2016-02-04 |
| PT2413913T (pt) | 2022-06-09 |
| RU2011143619A (ru) | 2013-05-10 |
| CA2757418A1 (en) | 2010-10-07 |
| AU2010231962B2 (en) | 2015-05-21 |
| DK2413913T3 (da) | 2022-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011010311A (es) | Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas. | |
| GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| MY183312A (en) | Pharmaceutical formulation | |
| WO2011153157A3 (en) | Benzoquinolone inhibitors of vmat2 | |
| PH12012502216A1 (en) | Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienyl-methylbenzene derivatives as inhibitors of sglt | |
| MD4556C1 (ro) | Compuşi inhibitori ai activităţii catehol O-metiltransferazei | |
| GEP20227397B (en) | Inhibitors of influenza viruses replication | |
| IN2014MN02598A (enExample) | ||
| IN2014CN04530A (enExample) | ||
| MX2012000414A (es) | Derivados piridin-4-ilo. | |
| WO2012030685A3 (en) | Indazole derivatives useful as erk inhibitors | |
| EP3626253A3 (en) | Stable formulations of linaclotide | |
| PH12013501704A1 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| MX2011012523A (es) | Esteres cetalicos de anhidropentitoles y usos de los mismos. | |
| EA201270741A1 (ru) | Пероральные композиции и липофильные соли метилналтрексона | |
| GEP20135744B (en) | Quinuclidine carbonate derivatives and medicinal compositions containing the same | |
| MX2011007267A (es) | Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina. | |
| PH12015502802A1 (en) | Formulation comprising a hypolipidemic agent | |
| BR112012011328A2 (pt) | inibidores de akt | |
| MX2019012939A (es) | Formulaciones que contienen linaclotida para administracion oral. | |
| MX2009007260A (es) | Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5). | |
| MX2011007451A (es) | Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina. | |
| EA201270302A1 (ru) | Безводные формы производных пиридина | |
| TN2012000105A1 (en) | Spirolactam derivatives and uses of same | |
| WO2011123524A3 (en) | Macrolide inhibitors of mtor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |